Post Profile






Novo Nordisk got beat out on one of the first big healthcare deals of the year — here's what the CEO is still looking for in an acquisition (NVO)

Novo Nordisk in January came out with a $3.1 billion bid for Belgian biotech Ablynx, one of the first signs of M&A in a now-busy year. Novo was ultimately beaten out by rival Sanofi, which acquired Ablynx for $4.8 billion. Novo CEO Lars Fruergaard Jorgensen told Business Insider that the company is still on the lookout for deals in the $2-3 billion range. 2018 is shaping up to be a big year for deals in the pharmaceutical industry.
read more

share

Related Posts


Ablynx signs Sanofi deal potentially worth up to $2.8 bln

Health : Reuters: Health

(Reuters) - French drugmaker Sanofi boosted its early-stage pipeline in immunology on Thursday by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).

Medivation just rejected Sanofi's $9.3 billion takeover bid (MDVN, SNY)

Business & Finance : Business Insider: Clusterstock

One of the bids for a San Francisco biotech has already fallen flat. On Friday, cancer drugmaker Medivation rejected pharma giant Sanofi's $9.3 billion takeover offer. The Sanofi bid was one of three major healthcare acquisitions th...

MORGAN STANLEY: Here are the 10 healthcare companies most likely to get bought this year

Business & Finance : Business Insider: Clusterstock

It's shaping up to be a big year for healthcare M&A. In the month of January alone, there was a total of $27.5 billion worth of deals, including a $9 billion deal for a cancer drugmaker and a bidding war for a Belgian biotech. US ta...

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid

Health : Reuters: Health

COPENHAGEN/BRUSSELS (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolsteri...

Sanofi in 3.9bn deal to acquire Ablynx

Business & Finance : Business Report

INTERNATIONAL - Sanofi agreed to buy Belgium’s Ablynx for 3.9 billion (R70.66bn), leapfrogging an unsolicited bid from rival Novo Nordisk to gain a potential blockbuster for a rare blood clotting disease. Paris-based Sanofi will pay...

Comments


Copyright © 2016 Regator, LLC